ReviewDiagnostics (Basel, Switzerland)2026
Advanced Eye Movement Features Measured by Quantitative Oculography as Candidate Biomarkers for Progressive Supranuclear Palsy.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Conventional qualitative eye movement examinations may miss subtle abnormalities, complicating early and accurate diagnosis of progressive supranuclear palsy (PSP). Quantitative oculography, represented by video-oculography (VOG), provides an objective digital assessment of eye movements. This review summarizes abnormalities in advanced eye movement tasks in PSP, including prosaccades (ProSs), antisaccades (ASs), memory-guided saccades (MGSs), predictive saccades (PSs), overlap saccades (OSs) and gap saccades (GSs), and considers their underlying pathophysiological mechanisms. Quantitative metrics from these tasks may help distinguish PSP subtypes and PSP from other neurodegenerative diseases, such as Parkinson's disease (PD), multiple system atrophy (MSA), corticobasal degeneration (CBD) and Alzheimer's disease (AD). Advanced eye movement measures are therefore promising candidate biomarkers for PSP diagnosis and longitudinal disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.